Dirk De Ruysscher, MD, PhD, Maastricht University Medical Center, Maastricht, Netherlands gives an update on the ongoing randomized Phase II STIMULI trial (NCT02046733) at the ESMO 2020 education weekend. The STIMULI trial investigates the efficacy and tolerability of the immunotherapy treatments nivolumab and ipilimumab in combination with chemoradiotherapy for patients with limited-stage small-cell lung cancer. Dr De Ruysscher tells us that the trial has not found benefits to progression-free survival (PFS) nor overall survival (OS) with the addition of nivolumab and ipilimumab, and 50% of patients were unable to receive the full course of immunotherapy due to its toxicity. Finally, Dr De Ruysscher outlines how biobanking will be used to investigate hematological profiles and other biomarkers to try and define a patient group that may benefit from the addition of immunotherapy to standard chemoradiotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).